Research Grade Coltuximab,100ug,HB996016-100ug,Abinscience

Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.

Host species	Chimeric
Isotype	IgG1-kappa
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names	SAR3419, CAS: 1269764-99-9
Note	For research use only. Not suitable for clinical or therapeutic use.